Form 4: Enliven Therapeutics Director Richard Heyman Sells Shares Under 10b5-1 Plan

Director Richard Heyman of Enliven Therapeutics sold 1,270 shares of common stock at a weighted average price of $14.5029, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 19, 2024, Richard A. Heyman, a director of Enliven Therapeutics, sold 1,270 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on July 17, 2023.
• The weighted average sale price was $14.5029, with individual trades ranging from $14.50 to $14.725.
• Following the transaction, Heyman directly owns 143,470 shares.
• Heyman also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 29,216 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock sale by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.

Stakeholder Impact

• The stock sale by a director could be perceived negatively by some shareholders, potentially leading to a slight decrease in stock price due to concerns about insider confidence.
• However, the sale was conducted under a pre-arranged 10b5-1 trading plan, which mitigates concerns about opportunistic trading based on inside information.

Key Dates